VanEck Biotech ETF reported 23 holdings worth US$396M as of Jun 30, 2026 (Form N-PORT)
As of Jun 30, 2026 · Filed Aug 26, 2026
VanEck Biotech ETF reported 23 holdings worth US$396M as of Jun 30, 2026. Largest: Amgen Inc., Gilead Sciences, Inc. and Vertex Pharmaceuticals Incorporated. Filed Aug 26, 2026 (Form N-PORT).
- Holdings
- 23
- Value as reported
- US$396M
The filing in full
| Company | Shares | Value as reported | % of portfolio |
|---|---|---|---|
| Amgen Inc. | 167K | US$60.3M | 15.2% |
| Gilead Sciences, Inc. | 400K | US$50.6M | 12.8% |
| Vertex Pharmaceuticals Incorporated | 72,485 | US$36M | 9.1% |
| Regeneron Pharmaceuticals, Inc. | 39,388 | US$24.6M | 6.2% |
| Revolution Medicines, Inc. | 111K | US$20.9M | 5.3% |
| Argenx Se | 21,198 | US$19.7M | 5.0% |
| Natera, Inc. | 71,677 | US$19.5M | 4.9% |
| Iqvia Holdings, Inc. | 88,160 | US$17M | 4.3% |
| Alnylam Pharmaceuticals, Inc. | 50,358 | US$15.2M | 3.8% |
| Biogen Inc. | 66,394 | US$14.3M | 3.6% |
| Moderna, Inc. | 190K | US$13.3M | 3.4% |
| Illumina, Inc. | 71,334 | US$12.5M | 3.2% |
| United Therapeutics Corporation | 20,628 | US$11.2M | 2.8% |
| Beone Medicines Ltd. Class A | 38,996 | US$11.1M | 2.8% |
| Insmed Incorporated | 99,048 | US$10.6M | 2.7% |
| Incyte Corporation | 86,946 | US$9.86M | 2.5% |
| Neurocrine Biosciences, Inc. | 48,865 | US$8.24M | 2.1% |
| Icon Plc | 43,319 | US$7.52M | 1.9% |
| Bio-techne Corp | 86,310 | US$6.1M | 1.5% |
| Charles River Laboratories International, Inc. | 26,203 | US$5.94M | 1.5% |
| Biomarin Pharmaceutical Inc. | 92,530 | US$5.29M | 1.3% |
| Qiagen N.v. | 108K | US$4.21M | 1.1% |
| Tempus Ai, Inc. | 67,091 | US$3.89M | 0.98% |